Nucleotide sequence for treating cancer and infection
OwnerMarc Zeicherinventor
Life of this patent
Estimating the term…
Abstract
A nucleotide sequence comprising the nucleotide sequence of a virus belonging to the group of autonomous parvoviruses, and at least one effector nucleotide sequence which encodes an effector polypeptide capable of effecting the destruction or the normalization of cancer cells or cells infected by virus, bacteria, or intra-cellular infectious parasites.
Claims21
A first nucleotide sequence comprising a second nucleotide sequence and a third nucleotide sequence, said second nucleotide sequence comprising the nucleotide sequence of an oncoselective autonomous parvovirus, and said third nucleotide sequence comprising at least one effector nucleotide sequence encoding an effector polypeptide, wherein said effector polypeptide effects the destruction or the normalization of cancer cells,
- wherein the effector nucleotide sequence comprises at least one sequence chosen from the group consisting of:
- a nucleotide sequence that encodes a cytotoxic polypeptide or at least one fragment of this polypeptide, and
- a nucleotide sequence that encodes a molecule which confers on a transfected cell sensitivity to a radioactive toxic agent.
A nucleotide sequence comprising the nucleotide sequence of an autonomous parvovirus, and at least one effector nucleotide sequence encoding a polypeptide which effects the destruction or normalization of cells infected by intracellular infectious parasites,
- wherein the effector nucleotide sequence comprises at least one sequence selected from the group consisting of:
- a nucleotide sequence that encodes a cytotoxic polypeptide or at least one fragment of this polypeptide, and
- a nucleotide sequence that encodes a molecule which confers on a transfected cell sensitivity to a radioactive toxic agent.
Dependencies are inferred from the claim text.